3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Experiencia de teduglutide como tratamiento del síndrome de intestino corto Translated title: Experience with teduglutide as a treatment for short bowel síndrome

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Resumen El síndrome de intestino corto (SIC) es un trastorno metabólico que produce malabsorción. Afecta a aquellos pacientes que han perdido, de forma anatómica o funcional, una parte de su intestino1. En adultos, la principal causa es la isquemia intestinal primaria o secundaria y menos frecuentemente puede ser consecuencia de una enfermedad inflamatoria intestinal o enteritis rádica. La mortalidad a medio plazo es alta debida al elevado riesgo de complicaciones por sepsis a causa del catéter, el sobrecrecimiento bacteriano o fallo hepático asociado a la nutrición parenteral (NP)2.

          Translated abstract

          Abstract Short bowel syndrome (SBS) is a metabolic disorder that causes malabsorption. It affects patients who have anatomically or functionally lost part of their intestine1. In adults, the main cause is primary or secondary intestinal ischemia and less frequently it may be a consequence of inflammatory bowel disease or radicular enteritis. Mid-term mortality is high due to the high risk of complications from catheter-related sepsis, bacterial overgrowth or liver failure associated with parenteral nutrition (PN)2.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome

          OBJECTIVES: In the pivotal 24-week, phase III, placebo-controlled trial, teduglutide significantly reduced parenteral support (PS) requirements in patients with short bowel syndrome (SBS). STEPS-2 was a 2-year, open-label extension of that study designed to evaluate long-term safety and efficacy of teduglutide. METHODS: Enrolled patients had completed 24 weeks of either teduglutide (TED/TED) or placebo (PBO/TED) in the initial placebo-controlled study or qualified for that study, but were not treated (NT/TED) because of full enrollment. Patients received subcutaneous teduglutide 0.05 mg/kg/day for up to 24 months (NT/TED and PBO/TED) or up to 30 months (TED/TED). Clinical response was defined as 20–100% reduction from baseline in weekly PS volume; baseline was considered the beginning of teduglutide treatment in the initial placebo-controlled study (TED/TED) or STEPS-2 (NT/TED and PBO/TED). Descriptive statistics summarized changes in efficacy and safety variables. RESULTS: Of 88 enrolled patients, 65 (74%) completed STEPS-2. The most common treatment-emergent adverse events were abdominal pain (34%), catheter sepsis (28%), and decreased weight (25%). Mean weight, body mass index, and serum albumin remained stable. In patients who completed the study, clinical response was achieved in 28/30 (93%) TED/TED, 16/29 (55%) PBO/TED, and 4/6 (67%) NT/TED patients. Mean PS volume reductions from baseline were 7.6 (66%), 3.1 (28%), and 4.0 (39%) l/week in the TED/TED, PBO/TED, and NT/TED groups, respectively. Thirteen patients achieved full enteral autonomy. CONCLUSIONS: In patients with SBS, long-term teduglutide treatment resulted in sustained, continued reductions in PS requirements. Overall health and nutritional status was maintained despite PS reductions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Spectrum of short bowel syndrome in adults: intestinal insufficiency to intestinal failure.

            Short bowel syndrome (SBS) refers to the malabsorptive state caused by physical or functional loss of portions of the small intestine, most commonly following extensive intestinal resection. Such resections hinder absorption of adequate amounts of macronutrients, micronutrients, electrolytes, and water, resulting in malnutrition, diarrhea, and dehydration. Clinical features of SBS vary along a continuum, depending on the extent and anatomy of intestine lost and the ability of the patient and the remaining intestine to compensate for the loss. The impact of SBS can be extensive, leading to diminished health-related quality of life because of its many physical and psychological effects on patients. SBS is associated with decreased survival; risk factors for SBS-related mortality include very short remnant small bowel, end-jejunal remnant anatomy, and arterial mesenteric infarction as primary cause. Although parenteral nutrition and/or intravenous fluid (PN/IV) is a life-saving measure for many patients with SBS, patients with the most severe malabsorption (ie, dependent on PN/IV) are at risk for severe, chronic complications and death. Patients' treatment needs vary depending on disease severity and resection type; thus, each patient should be individually managed. This review discusses the spectrum of disease in patients with SBS and presents common complications encountered by these patients to highlight the importance of individualized management and treatment.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              AGA technical review on short bowel syndrome and intestinal transplantation

                Bookmark

                Author and article information

                Journal
                ofil
                Revista de la OFIL
                Rev. OFIL·ILAPHAR
                Organización de Farmacéuticos Ibero-Latinoamericanos (Madrid, Madrid, Spain )
                1131-9429
                1699-714X
                March 2023
                : 33
                : 1
                : 95-97
                Affiliations
                [1] Almería orgnameHospital Universitario Torrecárdenas orgdiv1Servicio de Farmacia España edutejedor91@ 123456gmail.com
                [2] Valladolid orgnameHospital Universitario Río Hortega orgdiv1Servicio de Digestivo España
                Article
                S1699-714X2023000100017 S1699-714X(23)03300100017
                10.4321/s1699-714x2023000100017
                4036d981-1c6a-43a8-a094-1bd1a7e371aa

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                : 18 April 2021
                : 11 May 2021
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 9, Pages: 3
                Product

                SciELO Spain

                Categories
                Casos Clínicos

                insuficiencia intestinal,estado nutricional,nutrición parenteral,teduglutida,Glucagon-like peptide 2,intestinal adaptation,intestinal failure,nutritional status,parenteral nutrition,teduglutide,Péptido similar al glucagón 2,adaptación intestinal

                Comments

                Comment on this article